GlassScriptPhysician profile
Divya Shokeen
NPI 1205270832
$5,475.79
in general payments reported to CMS, 2019-2025
28 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $13.00 · 2021: $233 · 2022: $151 · 2023: $1,959 · 2024: $1,251 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,475 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,475.27 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $968.22 | 2023-2024 | Puraply |
| Merz North America, INC. | $646.34 | 2023-2024 | Xeomin |
| Genzyme Corporation | $544.20 | 2022-2025 | |
| Pfizer INC. | $404.97 | 2019-2025 | |
| Ucb, INC. | $350.45 | 2021-2025 | Bimzelx |
| Allergan, INC. | $328.61 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $243.01 | 2023-2025 | Odomzo, Blu-U, Winlevi |
| Regeneron Healthcare Solutions, INC. | $224.72 | 2022-2025 | Dupixent, Libtayo |
| Incyte Corporation | $212.42 | 2021-2025 | Opzelura |
| Abbvie INC. | $209.85 | 2023-2025 | Skyrizi |
| Botanix Sb INC | $175.48 | 2025 | Sofdra |
| Penumbra, INC. | $150.00 | 2019 | |
| Amgen INC. | $115.26 | 2024-2025 | Otezla |
| Lilly USA, LLC | $111.85 | 2021-2025 | Taltz, Ebglyss, Zepbound |
| Solta Medical, A Division of Bausch Health US, LLC | $108.53 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $92.37 | 2025 | Anzupgo, Adbry |
| Galderma Laboratories, L.P. | $90.72 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $83.89 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $79.47 | 2024-2025 | Sotyktu |
| Revance Therapeutics, INC. | $68.38 | 2024 | Daxxify |
| Biofrontera INC. | $54.60 | 2019-2024 | Ameluz, Rhodoled Xl, Xepi |
| Almirall LLC | $52.00 | 2024-2025 | Seysara, Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.48 | 2020-2025 | Cabtreo, Siliq |
| Boston Scientific Corporation | $28.41 | 2025 | Varithena Administration Pack |
| Janssen Biotech, INC. | $26.21 | 2024 | Tremfya |
| Genentech USA, INC. | $25.26 | 2023 | Xolair |
| Verrica Pharmaceuticals INC. | $21.88 | 2025 | Ycanth |
| Arcutis Biotherapeutics, INC. | $21.21 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Shokeen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.